What is Clinical Research?
History, Principles, and Modern Practice

1. Introduction: The Scientific and Regulatory Bedrock

Clinical research represents the definitive bridge between scientific theory and medical reality. It is the rigorous, systematic process through which hypothesized advances in biology, chemistry, and technology are translated into safe, effective interventions for human health. In an era where "evidence-based medicine" is the gold standard, clinical research serves as the engine of that evidence.

1.1 Defining the Discipline: A Tale of Two Agencies

While the term "clinical research" is often used broadly, its precise definition varies depending on which regulatory body is governing the activity.

1.2 Clinical Trials vs. Clinical Research

While all clinical trials are clinical research, not all clinical research constitutes a clinical trial. The key differentiator is prospective assignment. In a trial, the researcher actively controls who receives the intervention, whereas in an observational study, the researcher observes outcomes in patients already taking a treatment.

2. The Historical Evolution of Clinical Inquiry

To practice clinical research today is to operate within a framework built upon centuries of trial, error, and tragedy.

2.1 The Pre-Modern Era

The earliest recorded "clinical trial" appears in the Book of Daniel (562 BC), comparing a diet of meat versus legumes. In 1747, James Lind’s Scurvy Trial aboard the HMS Salisbury established the concept of comparative groups when he successfully treated sailors with citrus fruits.

2.2 The 20th Century: The Rise of Regulation

• The Elixir Sulfanilamide Tragedy (1937): A toxic antibiotic formulation killed over 100 people, leading to the FD&C Act of 1938, which mandated that manufacturers prove a drug was safe before marketing.
• The Thalidomide Tragedy (1960s): Birth defects caused by thalidomide led to the Kefauver-Harris Amendments of 1962, requiring proof of efficacy (not just safety) through "adequate and well-controlled investigations".

3. The Ethical Framework: The Belmont Report and GCP

The ethical conduct of clinical research is not subjective; it is codified in federal regulation. The Belmont Report (1979), issued by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, provides the philosophical framework that underpins all U.S. human subjects research protections.

Good Clinical Practice (GCP): The Operational Standard

While the Belmont Report provides the ethical philosophy, Good Clinical Practice (GCP) provides the operational standard. ICH E6(R3), finalized January 2025, is the current international GCP standard. It supersedes E6(R2) and reflects the field's shift toward risk-based approaches, technology-enabled oversight, and proportionate monitoring.

The foundational GCP principle in E6(R3) is that the rights, safety, and well-being of trial participants are the most important considerations and must prevail over the interests of science and society. This is not a aspiration; it is a compliance requirement that governs every decision a CRC makes from consent through closeout.

4. The Anatomy of Drug Development

The journey of a new drug from laboratory discovery to first marketing approval typically takes 10 to 15 years and is structured into sequential phases to systematically reduce risk before larger and more expensive trials begin. Each stage builds on the evidence generated in the previous one.

4.1 Preclinical Research

Before a drug candidate is administered to any human, it must undergo extensive in vitro (cell culture) and in vivo (animal) testing to characterize its pharmacology, toxicology, and pharmacokinetics. The goal is not to prove the drug is safe for humans, but to establish that the risk of initial human exposure is scientifically justified and that the proposed dose range is appropriate.

If preclinical results are sufficiently promising, the sponsor submits an Investigational New Drug (IND) application to the FDA under 21 CFR Part 312. The FDA has 30 days to review and either allow human testing to proceed or place the investigation on clinical hold. The IND creates the regulatory framework within which all site activities, protocol amendments, and safety reporting occur.

Source: FDA: The Drug Development Process

5. Trial Design and Methodology

The scientific integrity of a trial depends on its design. The Randomized Controlled Trial (RCT) is the gold standard for establishing causation because it is the only design that can reliably eliminate confounding. Understanding trial design helps CRCs understand why specific protocol procedures exist and why deviations from them matter.

• Eliminating Selection Bias

  Randomization

  Participants are assigned to treatment arms by a chance process, not by investigator preference or participant choice. This distributes known and unknown confounding variables equally across arms, ensuring that any observed difference in outcomes is attributable to the treatment rather than baseline group differences. CRCs must follow the randomization procedure exactly as specified in the protocol — unauthorized changes to randomization are major protocol deviations.

• Preventing Observer Effect

  Blinding (Masking)

  In a single-blind trial, participants do not know their treatment assignment. In a double-blind trial, neither participants nor the site team know, with treatment assignment held by an unblinded pharmacist or the sponsor. Blinding prevents the placebo effect from inflating patient-reported outcomes and prevents investigator bias from influencing assessments. Unblinding procedures are specified in the protocol; unauthorized unblinding is a serious GCP deviation.

• Statistical Power

  Sample Size and Endpoints

  The protocol specifies a primary endpoint and a sample size calculated to detect a clinically meaningful difference with defined statistical power, typically 80% or 90%. The primary endpoint is the pre-specified outcome that will be used to determine trial success or failure. Secondary and exploratory endpoints provide additional information but do not define the trial's regulatory outcome. CRCs must collect primary endpoint data exactly as specified; errors or missing data at the primary endpoint can compromise the entire trial's regulatory submission.

6. The Clinical Research Workforce

Clinical trials require a coordinated team with distinct roles, responsibilities, and regulatory obligations. At the site level, three roles form the operational core.

7. Decentralized Trials and the Changing CRC Role

The classic clinical trial model, where all study activities occur at a physical research site, has been evolving since at least the COVID-19 pandemic period, when many sites were forced to adapt to remote or hybrid conduct. That evolution is now formalized in regulatory guidance and reflected in how sponsors design studies.

Decentralized Clinical Trials (DCTs)

A decentralized clinical trial is one in which some or all trial activities are conducted at locations other than the traditional research site, including participants' homes. DCT elements include: remote informed consent, telehealth visits, direct-to-participant drug shipment, electronic patient-reported outcomes (ePRO), and wearable or digital health technologies (DHTs) that collect continuous data between visits.

In September 2024, the FDA issued final guidance on Decentralized Clinical Trials for Drugs, Biological Products, and Devices, providing sponsors and sites with a regulatory framework for DCT conduct. The guidance addresses informed consent in DCT settings, participant safety monitoring at home, the use of local healthcare providers to conduct some procedures, and data integrity considerations for remotely collected data.

Risk-Based Quality Management (RBQM)

Formalized in ICH E6(R3), RBQM requires sponsors and sites to identify Critical to Quality (CtQ) factors at the protocol level: the specific data points and procedures where errors, omissions, or variability would most affect participant safety or the validity of trial results. Monitoring and quality oversight are then focused proportionally on these high-risk areas, rather than applying equal scrutiny to every data point.

For CRCs, RBQM means understanding which protocol elements are CtQ for their specific study and why. A missed primary endpoint assessment is not the same as a missing secondary questionnaire. CRCs who understand the CtQ hierarchy can make better real-time decisions about where to direct their attention and which deviations require immediate escalation versus standard deviation reporting.